Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
BackgroundArrhythmias are prevalent cardiac disorders with significant impacts on patient quality of life and mortality. Amiodarone, a class III antiarrhythmic agent, is widely used to manage both atrial and ventricular arrhythmias due to its efficacy in prolonging the cardiac action potential and i...
Saved in:
Main Authors: | Jingrong Yang, Mengfan You, Jingxin Wang, Rongfei Sun, Lili Han, Xiaonan Liu, Kaibin Niu, Kaidi Xing, Juanping Sun, Wenge Su, Yifei Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1517616/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early amiodarone or lidocaine administration during in-hospital cardiac arrest caused by shockable rhythms
by: Rafael C. Paganoni, et al.
Published: (2025-03-01) -
A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01) -
Adverse events in the nervous system associated with blinatumomab: a real-world study
by: Wen Gao, et al.
Published: (2025-02-01) -
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01) -
Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)